Nika Pharmaceuticals, Inc (NIKA) Cash from Financing Activities (2021 - 2023)

Nika Pharmaceuticals (NIKA) has 3 years of Cash from Financing Activities data on file, last reported at $10000.0 in Q3 2023.

• Quarterly Cash from Financing Activities rose 211.72% year-over-year to $10000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $79565.0 (up 229.05% YoY) and the FY2022 annual result came in at $34180.0, up 153.19% from the prior year.
• Cash from Financing Activities fell to $10000.0 in Q3 2023, from $34400.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $34400.0 in Q2 2023 to a low of $2000.0 in Q2 2021.
• A 3-year average of $10476.8 and a median of $6000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 548.6% in 2022, down 19.8% in 2022.
• Tracing NIKA's Cash from Financing Activities over 3 years: stood at $2000.0 in 2021, then soared by 500.0% to $12000.0 in 2022, then fell by 16.67% to $10000.0 in 2023.
• The last three Cash from Financing Activities figures came in at $10000.0 (Q3 2023), $34400.0 (Q2 2023), and $23165.0 (Q1 2023), per Business Quant data.